Clinical Trials on Laboratory Confirmed Influenza

Total 2431 results

National Institute of Allergy and Infectious Diseases...

Terminated

Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers

Influenza | Influenza Immunisation

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination

Influenza | Influenza Immunisation

United States
Sinovac Biotech Co., Ltd

Completed

Lot-to-lot Consistency of Quadrivalent Influenza Vaccine (Split Virion), Inactivated

Seasonal Influenza

China
ModernaTX, Inc.

Completed

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

Seasonal Influenza

Philippines, Australia, Colombia, Argentina, Panama
FluGen Inc
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old

Influenza Vaccine

United States
FluGen Inc
United States Department of Defense

Completed

Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults

Influenza Vaccine

United States
Sinovac Biotech Co., Ltd

Completed

A Clinical Trial of Quadrivalent Influenza Vaccine in Children Aged 3-8 Years Old

Seasonal Influenza

China
FluGen Inc

Completed

Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines

Influenza A

United States
National Institute of Allergy and Infectious Diseases...

Completed

H3N2 M2SR in Pediatric Population

Influenza | Influenza Immunisation

United States
MedImmune LLC

Completed

A Phase 2 Study to Evaluate Immune Responses of FluMist®

Influenza Vaccine

United States
National Institute of Allergy and Infectious Diseases...

Completed

Age and Response to Flu Vaccines

Influenza | Influenza Immunisation

United States
Ology Bioservices

Completed

Yearly Strain Variation Study, 2010/2011

Influenza | Seasonal Influenza

Austria
National Institute of Allergy and Infectious Diseases...

Completed

Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine

Influenza | Influenza Immunisation

United States
GlaxoSmithKline

Completed

Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults

Influenza | Influenza Vaccines

Taiwan, Hong Kong, Thailand, Singapore
Celltrion

Completed

A Study to Evaluate the Efficacy and Safety of CT-P27 in an Influenza Challenge Model

Influenza A

United Kingdom
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Qingdao Municipal Hospital; Beijing Luhe Hospital; Cangzhou People's Hospital; First... and other collaborators

Unknown

Evaluate the Safety and Efficacy of Xiyanping in Pediatric Participants With Severe Influenza-Like Symptoms

Severe Influenza

China
University of Warwick
University Hospital Birmingham

Completed

An Improvement Project Around Staffs' Influenza Vaccine Uptake

Influenza Vaccination

United Kingdom
Advagene Biopharma Co. Ltd.

Completed

A Phase 2, Double-blind Study to Evaluate Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult

Influenza Infection

Taiwan
Adimmune Corporation

Completed

Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults

Pandemic Influenza

Taiwan
Duke University
United States Department of Defense; Imperial College of London

Unknown

Biomarkers Predicting Infectivity in an Experimental Human Influenza Model (PRESAGE)

Influenza A

United Kingdom
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly Subjects

Influenza | Seasonal Influenza

United Kingdom
Novartis Vaccines

Completed

Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and Above

Human Influenza

Germany
Immune Targeting Systems Ltd

Completed

Safety, Tolerability, Efficacy and Immunogenicity of an Influenza A Vaccine (FP-01.1) in Healthy Volunteers Following Virus Challenge

Influenza A

United Kingdom
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010

Seasonal Influenza

Italy
Ology Bioservices

Completed

Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)

Influenza | Pandemic Influenza

United States
Ology Bioservices

Completed

Yearly Strain Variation Study, 2009/2010

Influenza | Seasonal Influenza

Austria
Ology Bioservices

Completed

A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents

Influenza | Pandemic Influenza

Austria, Germany
University of British Columbia
PHAC/CIHR Influenza Research Network

Completed

Comparison of 4 Influenza Vaccines in Seniors (PCIRNRT09)

Influenza Vaccine

Canada
Novartis Vaccines

Completed

Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age

Influenza Disease

Argentina, Australia, Chile, Philippines, South Africa
Columbia University

Completed

Adult Influenza Vaccination Text Message Reminders

Influenza Vaccination

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age

Human Influenza

Belgium
Novartis Vaccines

Completed

Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above

Human Influenza

Germany
Novavax
Department of Health and Human Services

Completed

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2

Influenza (Pandemic)

United States
Novavax

Completed

Safety, Reactogenicity and Immunogenicity of an H5N1 VLP

Pandemic Influenza

United States
St. Jude Children's Research Hospital

Completed

Surveillance of Influenza Virus Shedding and Immunologic Response in Immunocompromised Children and Young Adults

Influenza Virus

United States
International Centre for Infectious Diseases, Canada
GlaxoSmithKline

Unknown

H1N1 Vaccine Safety in Manitoba, Canada

H1N1 Influenza

Canada
Hualan Biological Engineering, Inc.

Completed

Phase IV Clinical Trial of an Inactivated Influenza Split Vaccine

Human Influenza

China
Kirby Institute
National Health and Medical Research Council, Australia

Withdrawn

A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Volunteers Who Receive Long-term Prophylaxis Against Pandemic Influenza: PIPET B (PIPET B)

Pandemic Influenza

Australia
Kirby Institute
National Health and Medical Research Council, Australia

Withdrawn

A Prospective Study to Examine the Effectiveness and Safety of Antivirals in Volunteers Who Receive Short-term Prophylaxis Against Pandemic Influenza (PIPET C)

Pandemic Influenza

Australia
Novartis Vaccines

Completed

Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2010/2011

Seasonal Influenza

Germany
Abbott Biologicals
Quintiles, Inc.

Completed

Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Elderly

Influenza Vaccines

Czech Republic, Estonia, Lithuania
Dalhousie University
GlaxoSmithKline; Canadian Institutes of Health Research (CIHR); IWK Health Centre

Completed

Evaluation of Seasonal Influenza Vaccine for 2010-2011 in Young Children

Seasonal Influenza

Canada
The University of Hong Kong

Completed

Convalescent Plasma Treatment in Severe 2009 H1N1 Infection

Influenza A

China
Seoul National University Hospital

Unknown

The Impact of Vitamin on the Clinical Course in Cases Infected by Novel H1N1 Influenza Virus A

H1N1 Influenza

Korea, Republic of
Assistance Publique - Hôpitaux de Paris
Orakine Ltd, Dublin, Ireland

Terminated

Effect of the Interferon Alpha Citizen by Sub-Lingual Way on the Humoral Immunizing Answer (GP-INFA)

Influenza Infection

France
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of a Inactivated Influenza Vaccine When Administered to Non Elderly Adults and Elderly Subjects.

Influenza Disease

Italy
Mexican Emerging Infectious Diseases Clinical Research...
National Institute of Allergy and Infectious Diseases (NIAID); Coordinación...

Completed

A Study to Determine the Causes and Identify Increases in Influenza-Like Illness (ILI) in Mexico

Acute Respiratory Infections | Influenza Nos or Influenza-like Illness

Mexico
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine

Influenza | Influenza, Human | Influenza A Virus, H5N1 Subtype | Flu, Human | Flu, Avian

Australia, Germany, Italy
Sanofi Pasteur, a Sanofi Company

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022/23

Influenza (Healthy Volunteers)

Germany, Finland
Sanofi Pasteur, a Sanofi Company

Completed

Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea

Influenza (Healthy Volunteers)

Korea, Republic of

3

Subscribe